May 7th 2021, 9:00pm
Interim results from a phase 2 study demonstrated that patients inoperable or advanced intrahepatic cholangiocarcoma and a FGFR2 gene mutation had a disease control rate of 79% when treated with derazantinib.
May 4th 2021, 3:00pm
Members of an FDA committee recently voted in favor of upholding Keytruda’s accelerated approval indication for the treatment of patients with advanced hepatocellular carcinoma who had previously received treatment with Nexavar. However, the committee narrowly voted against maintaining Opdivo’s accelerated approval in the same patient population.
April 30th 2021, 9:00pm
As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.
April 29th 2021, 1:00pm
Here is a list of some recent trials that launched within the cancer space in April.
April 13th 2021, 3:00pm
A 500 mg dose of Tepmetko, a MET inhibitor, in patients with hepatocellular carcinoma who were previously treated with Nexavar led to a 12-week progression-free survival rate of 63.3%.
April 9th 2021, 6:00pm
CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.
March 19th 2021, 9:00pm
Patients with this liver cancer subtype do not need to be hospitalized to receive this treatment and, according to the agent’s manufacturer, Boston Scientific, can typically receive the therapy in approximately an hour during an outpatient procedure.
March 17th 2021, 6:00pm
Genomic testing has allowed patients to receive more specific drugs that target mutations in their tumors.
February 25th 2021, 10:00pm
Following resection with radiotherapy increased survival rates for patients compared with those who did not receive the additional treatment.
January 27th 2021, 7:00pm
There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.
How Can Cancer Survivors Help The Newly Diagnosed?
CURE Honors World Ovarian Cancer Day
Derazantinib May Demonstrate Promising Disease Control in Some Patients With Cholangiocarcinoma
You May Have Second Thoughts When Receiving a Cancer Diagnosis
